REFERENCES
0.
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
3. Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
4. Brown AM, Kassab I, Massani M, et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Medicine. 2022;12:2590-9.
5. Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies. Cancers. 2020;12:1914.
6. Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons. World J Gastroenterol. 2021;27:7462-79.
7. Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624-36.
8. Lee YB, Nam JY, Cho EJ, et al. A Phase I/IIa Trial of Yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma. Clin Cancer Res. 2023;29:3650-8.
9. Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol. 2023;29:1054-75.
10. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681-93.
11. Teo J, Goh BK. Contra-lateral liver lobe hypertrophy after unilobar Y90 radioembolization: an alternative to portal vein embolization? World J Gastroenterol. 2015;21:3170-3.
12. Molvar C, Lewandowski R. Yttrium-90 radioembolization of hepatocellular carcinoma-performance, technical advances, and future concepts. Semin intervent Radiol. 2015;32:388-97.
13. Lewandowski R, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin intervent Radiol. 2006;23:064-72.
14. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79:163-71.
15. Busse NC, Al‐ghazi MSAL, Abi‐Jaoudeh N, et al. AAPm medical physics practice guideline 14.a: yttrium-90 microsphere radioembolization. J Appl Clin Med Phys. 2023;25:e14157.
16. Boas FE, Bodei L, Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes. J Nucl Med. 2017;58 Suppl:104S-11S.
17. Wagemans ME, Kunnen B, Stella M, et al. Comparison of 3 different therapeutic particles in radioembolization of locally advanced intrahepatic cholangiocarcinoma. J Nucl Med. 2024;65:272-8.
18. Villalobos A, Arndt L, Cheng B, et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres. J Vasc Interv Radiol. 2023;34:1226-34.
19. Gulec SA, Mcgoron AJ. Radiomicrosphere dosimetry: principles and current state of the art. Semin Nucl Med. 2022;52:215-28.
20. Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial radioembolization dosimetry in 2022. Cardiovasc Intervent Radiol. 2022;45:1608-21.
21. Feely M, Tondon R, Gubbiotti M, et al. Gastrointestinal tract injury by yttrium-90 appears largely restricted to resin microspheres but can occur years after embolization. Am J Surg Pathol. 2022;46:1234-40.
22. Kis B, Gyano M. Radiation pneumonitis after yttrium-90 radioembolization: a systematic review. J Vasc Interv Radiol. 2025;36:207-18.
23. Hickey RM, Lewandowski RJ, Salem R. Yttrium-90 radioembolization for hepatocellular carcinoma. Semin Nucl Med. 2016;46:105-8.
24. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives: Hepatology. Hepatology. 2013;58:2188-97.
25. Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. BJR. 2016;89:20150943.
26. Garin E, Tselikas L, Guiu B, et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65:264-9.
27. Zhang R, Yao Y, Gao H, Hu X. Mechanisms of angiogenesis in tumour. Front. Oncol. 2024;14:1359069.
28. Wang L, Geng H, Liu Y, et al. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm. 2023;4:e343.
29. Gajewski TF, Schreiber H, Fu Y. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014-22.
30. Tong J, Tan Y, Ouyang W, Chang H. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential. Exp Hematol Oncol. 2025;14:65.
31. Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164-74.
32. Öcal O, Schütte K, Zech CJ, et al. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. Eur J Nucl Med Mol Imaging. 2022;49:4716-26.
33. Chow PK, Gandhi M, Tan S, et al. ; on behalf of Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913-21.
34. Facciorusso A, Bargellini I, Cela M, Cincione I, Sacco R. Comparison between Y90 radioembolization plus sorafenib and Y90 radioembolization alone in the treatment of hepatocellular carcinoma: a propensity score analysis. Cancers. 2020;12:897.
35. Qin S, Chen M, Cheng A, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2023;402:1835-47.
36. Hack SP, Spahn J, Chen M, et al. IMbrave 050: A phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020;16:975-89.
37. Yu S, Yu M, Keane B, et al. A pilot study of pembrolizumab in combination with y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma. The Oncologist. 2024;29:270-e413.
38. Tai D, Loke K, Gogna A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:1025-35.
39. Fenton SE, Kircher SM, Mulcahy MF, et al. A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer. J Clin Oncol. 2021;39:e16183.
40. Centers for Disease Control and Prevention. Study of [Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant]: NCT07059494. CDC. Updated November 4, 2025. https://clinicaltrials.gov/study/NCT07059494. [Accessed on 20 May 2026].
41. Centers for Disease Control and Prevention. Study of [Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma]: NCT06867432. CDC. Updated March 10, 2025. https://clinicaltrials.gov/study/NCT06867432. [Accessed on 20 May 2026].
42. Centers for Disease Control and Prevention. Study of [Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma]: NCT05809869. CDC. Updated April 12, 2024. https://clinicaltrials.gov/study/NCT05809869. [Accessed on 20 May 2026].
43. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138:52-64.
44. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2.
45. Jones A, Degregorio P, Sung MW, Ramji Z, Ren M, Baron AD. Characterization and management of adverse reactions in patients with unresectable hepatocellular carcinoma treated with lenvatinib. JADPRO. 2023;14:598-607.
46. Kulik L, Vouche M, Koppe S, et al. Prospective randomized pilot study of Y90 +/− sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014;61:309-17.
47. Ramos-casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38.
48. Zhan C, Ruohoniemi D, Shanbhogue KP, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31:25-34.
49. Malone CD, Bajaj S, He A, et al. Combining radioembolization and immune checkpoint inhibitors for the treatment of hepatocellular carcinoma: the quest for synergy. J Vasc Interv Radiol. 2025;36:414-424.e2.
50. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-55.
51. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-42.
52. Llovet JM, Di Bisceglie AM, Bruix J, et al. ; for the panel of experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. JNCI: J Nat Cancer I. 2008;100:698-711.
